SCHEMBL4889134

SCHEMBL4889134

CC(C)(C)OC(=O)N(CCBr)Cc1ccc2c(c1)OCO2

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 2/20 0.49
CYP3A4 P08684 2/20 0.46
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.44
APOBEC3A P31941 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
PAX8 Q06710 1/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 2/20 0.41
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562272 0.93 TSHR (0.50) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3559192 0.89 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3569305 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3561195 0.86 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3563503 0.85 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3556105 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3567257 0.84 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3556098 0.84 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3563466 0.82 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1
SCHEMBL3566724 0.82 GAA (0.48) ALDH1A1SMN1; SMN2TSHRCYP3A4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293942-A1 Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives COUSINS RUSSELL D 2008-11-27 US disclosed
WO-2007062417-A1 METHODS OF PREPARING 2-IMIDAZOL-1-YL-4-METHYL-6-PYRROLIDIN-2-YL-PYRIMIDINE AND 4-(1-ALKYLPYRROLIDIN-2-YL)-2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDINE DERIVATIVES KALYPSYS, INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293942-A1 Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives NOS2, NOS1, NOS3 ALDH1A1 1435/4885SMN1; SMN2 1853/4885TSHR 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.